St. Jude Medical, Inc. STJ is expected to gain faster FDA approval for its Burst-technology enabled products, on the back of positive data from the SUNBURST study. The clinical study showed that a higher number of patients chose Burst stimulation over Spinal Cord Stimulation (SCS).
The results, presented at the 19th annual meeting of the North American Neuromodulation Society, demonstrated that more patients opt for Burst stimulation, which usually provides lower amount of paresthesia (an unusual sensation due to pressure on peripheral nerves).
The SUNBURST study enrolled 100 patients from 20 centers across the U.S. The patients were then randomly chosen to receive either tonic stimulation prior to Burst stimulation, or Burst stimulation before tonic stimulation. The examination of the first 85 patients established the superiority of Burst stimulation to traditional SCS.
Meanwhile, 69.4% of patients enrolled in the SUNBURST study favored Burst stimulation to tonic SCS for chronic pain treatment. While 91% patients confirmed a decrease in paresthesia during treatment with Burst stimulation, 65% were free from paresthesia.
It is to be noted that the company has recently announced the European launch of Proclaim Elite – upgradeable and non-rechargeable SCS system approved to deliver burst stimulation.
We believe the results from the clinical study will also boost the demand for St. Jude’s Burst products globally. It is encouraging for the investors to note that, at present, the company has the sole right to deliver Burst stimulation outside the domestic market.
Zacks Rank & Key Picks
St. Jude carries a Zacks Rank #3 (Hold).
A couple of better-ranked stocks in the same space include Masimo MASI, Olympus Corp OCPNY and Natus Medical BABY. All the stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment